Ratings Surperformance

Trader
Investor
Global
Quality
ESG MSCI
-
Ratings Surperformance© - Regeneron Pharmaceuticals, Inc.

Ratings ESG MSCI

Ratings ESG MSCI - Regeneron Pharmaceuticals, Inc.

Ratings Regeneron Pharmaceuticals, Inc.: Strengths and Weaknesses

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
  • The company presents an interesting fundamental situation from a short-term investment perspective.
Highlights: Regeneron Pharmaceuticals, Inc.
  • The earnings growth currently anticipated by analysts for the coming years is particularly strong.
  • The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
  • The group's activity appears highly profitable thanks to its outperforming net margins.
  • The company is in a robust financial situation considering its net cash and margin position.
  • The company has a low valuation given the cash flows generated by its activity.
  • Over the last twelve months, the sales forecast has been frequently revised upwards.
  • Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
  • For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
  • For the past twelve months, EPS forecast has been revised upwards.
  • The group usually releases upbeat results with huge surprise rates.
Weaknesses: Regeneron Pharmaceuticals, Inc.
  • The company is not the most generous with respect to shareholders' compensation.
  • Most analysts agree on a negative opinion with regard to the stock. Indeed, the average consensus issues recommendations to underperform or sell.
  • The overall consensus opinion of analysts has deteriorated sharply over the past four months.

Rating Financials

Regeneron Pharmaceuticals, Inc. SectorBrazil

Fundamentals

Growth

Revenue growth

EPS growth

FCF growth

Profitability

EBITDA Margin

EBIT Margin

Net Margin

Capital Efficiency

ROA

ROCE

ROE

Financial Health

Gearing

Leverage

Capital Intensity

Balance sheet growth

Long Term balance sheet growth

Long term revenue growth

Long term EPS growth

More ratings
Fundamental Rankings - Regeneron Pharmaceuticals, Inc.

Rating Valuation

Regeneron Pharmaceuticals, Inc. SectorBrazil

Global Valuation

Enterprise Value

EV/Revenue

EV/EBITDA

EV/FCF

Equity Valuation

P/E

PBR

Dividend Yield

EV/EBIT

CAPEX/Revenue

More ratings
Fundamental Rankings - Regeneron Pharmaceuticals, Inc.

Rating Consensus

Regeneron Pharmaceuticals, Inc. SectorBrazil

Consensus

Analysts' buy/sell recommendations

Analysts' recommendations evolution (1 year)

Analysts' recommendations evolution (4 months)

Analysts' target price

Analysts' target price evolution (1 year)

Analysts' target price evolution (4 months)

Analysts' recommendations evolution (7 days)

Target Price evolution (7 days)

More ratings
Fundamental Rankings - Regeneron Pharmaceuticals, Inc.

Rating Business Predictability

Regeneron Pharmaceuticals, Inc. SectorBrazil

Visibility

Analysts' coverage

Financial estimates divergence

Analysts' recommendations divergence

Analysts' Target price divergence

Surprise rates

Fundamental Rankings - Regeneron Pharmaceuticals, Inc.

Rating Revisions

Regeneron Pharmaceuticals, Inc. SectorBrazil

Financial revisions

Revenue revisions (1 year)

Revenue revisions (4 months)

EPS revisions (1 year)

EPS revisions (4 months)

EPS revisions (7 days)

Revenue revisions (7 days)

More ratings
Fundamental Rankings - Regeneron Pharmaceuticals, Inc.


Capi.($) Investor ESG MSCI Fundamentals Financial revisions Global Valuation Visibility Consensus
73.76B -
1,032B
A
614B
BBB
471B
AAA
-
350B
AA
337B
AA
268B
AAA
246B
A
218B
BBB
179B
AA
Average 378.86B
AA
Weighted average by Cap.
AA
  1. Stock Market
  2. Stocks
  3. REGN Stock
  4. REGN34 Stock
  5. Ratings Regeneron Pharmaceuticals, Inc.